Ji-Ching Lai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ji-Ching Lai has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Jung Li
Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital , Kaohsiung
2 shared publications - Pei-Yi Chu
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan
2 shared publications - Chang-Shen Lin
Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
1 shared publication - Chih-Jan Ko
Department of General Surgery, Changhua Christian Hospital, Changhua 500, Taiwan
1 shared publication - Chih-Yung Wen
The Hong Kong Polytechnic University
1 shared publication Chin-Yih Hong
Graduate Institute of Biomedical Engineering, National Chung Hsing University, Taichung, Taiwan
1 shared publication
Latest Publications
- Open Access
- 24 October 2020
- Published by MDPI AG in Biomedicines
- Vol. 8 (11) , 451
A Novel Biomarker Driving Poor-Prognosis Liver Cancer: Overexpression of the Mitochondrial Calcium Gatekeepers
Several studies have indicated the biological role of mitochondrial Ca2+ uptake in cancer pathophysiology; however, its implications in predicting the prognosis of hepatocellular carcinoma (HCC) are not yet fully understood. Here, we collected tumor specimens and adjacent normal liver tissues from 354 confirmed HCC patients and analyzed the levels of cyclic adenosine monophosphate (cAMP) responsive element binding protein 1 (CREB), mitochondrial calcium uniporter (MCU), mitochondrial calcium uptake 1 and 2 (MICU1, MICU2) using bioinformatics, qRT-PCR, and immunohistochemistry (IHC), and their relationship with clinicopathological characteristics and prognosis. HCC patients with low CREB/MICU1 and high MCU/MICU2 expression exhibited poor survival rate and prognosis in overall survival (OS) and disease-free survival (DFS) analyses. Low CREB/MICU1 and low MICU1 alone indicated poor prognosis in stage I/II and III/IV patients, respectively. In the poor differentiation/undifferentiation group, low expression of MICU1 indicated poor clinical outcomes. Low CREB/MICU1 expression suggested poor outcomes in patients with or without hepatitis B virus (HBV) infection and poor prognosis in the HCV infection group. In the non- hepatitis C virus (HCV) infection group, low MCU1 indicated a poor prognosis. Multivariate analysis demonstrated that CREB and MICU1 expression showed prognostic significance. This study demonstrates the prognostic significance of CREB, MCU, MICU1, and MICU2, in predicting HCC outcomes. Low CREB/MICU1 and high MCU/MICU2 in HCC tissues are associated with poor prognosis, thus offering a novel perspective in the clinical management for HCC patients.
- 24 October 2020
- Published by MDPI AG in Biomedicines
- Vol. 8 (11) , 451
Open AccessA Novel Biomarker Driving Poor-Prognosis Liver Cancer: Overexpression of the Mitochondrial Calcium Gatekeepers
Several studies have indicated the biological role of mitochondrial Ca2+ uptake in cancer pathophysiology; however, its implications in predicting the prognosis of hepatocellular carcinoma (HCC) are not yet fully understood. Here, we collected tumor specimens and adjacent normal liver tissues from 354 confirmed HCC patients and analyzed the levels of cyclic adenosine monophosphate (cAMP) responsive element binding protein 1 (CREB), mitochondrial calcium uniporter (MCU), mitochondrial calcium uptake 1 and 2 (MICU1, MICU2) using bioinformatics, qRT-PCR, and immunohistochemistry (IHC), and their relationship with clinicopathological characteristics and prognosis. HCC patients with low CREB/MICU1 and high MCU/MICU2 expression exhibited poor survival rate and prognosis in overall survival (OS) and disease-free survival (DFS) analyses. Low CREB/MICU1 and low MICU1 alone indicated poor prognosis in stage I/II and III/IV patients, respectively. In the poor differentiation/undifferentiation group, low expression of MICU1 indicated poor clinical outcomes. Low CREB/MICU1 expression suggested poor outcomes in patients with or without hepatitis B virus (HBV) infection and poor prognosis in the HCV infection group. In the non- hepatitis C virus (HCV) infection group, low MCU1 indicated a poor prognosis. Multivariate analysis demonstrated that CREB and MICU1 expression showed prognostic significance. This study demonstrates the prognostic significance of CREB, MCU, MICU1, and MICU2, in predicting HCC outcomes. Low CREB/MICU1 and high MCU/MICU2 in HCC tissues are associated with poor prognosis, thus offering a novel perspective in the clinical management for HCC patients.
- Open Access
- 9 March 2020
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2020, 1-2
Diagnostic, Prognostic, and Predictive Biomarkers in Breast Cancer
Breast cancer is the most frequently diagnosed cancer type and the second leading cause of cancer-related deaths among women worldwide. e causes of breast cancer are not yet fully known, although a number of risk factors have been identified. Tumor biomarker is a term used to describe potential markers of cancer development and progression. As we explore these biomarkers further, we must try to understand the underlying mechanisms of tumor development, as we move along the path to discovery of novel therapies that will increase our ability to offer personalized patient care in the future. With the migration of advanced high throughput technologies, such as Next Generation Sequencing from clinical practice, biomarker research and discovery are poised to explode once again. Translation of novel biomarkers into clinical practice and diagnostic laboratories is coupled with regulatory and administrative requirements that must be met, while collaboration between research institutions, industry, and the private sector drives further advancements in the field of breast cancer biomarker discovery and application. e aim of this special issue is to provide new findings regarding molecular pathways and biomarkers that could improve the diagnosis and the prognostic classification of breast cancers, their application in the clinical setting, and their potential utility in personalized patient therapy. e total of submissions is 50. After single-blind peer review by at least two reviewers, 14 papers were finally accepted to be published. e accepted rate is 28%.
- 9 March 2020
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2020, 1-2
Open AccessDiagnostic, Prognostic, and Predictive Biomarkers in Breast Cancer
Breast cancer is the most frequently diagnosed cancer type and the second leading cause of cancer-related deaths among women worldwide. e causes of breast cancer are not yet fully known, although a number of risk factors have been identified. Tumor biomarker is a term used to describe potential markers of cancer development and progression. As we explore these biomarkers further, we must try to understand the underlying mechanisms of tumor development, as we move along the path to discovery of novel therapies that will increase our ability to offer personalized patient care in the future. With the migration of advanced high throughput technologies, such as Next Generation Sequencing from clinical practice, biomarker research and discovery are poised to explode once again. Translation of novel biomarkers into clinical practice and diagnostic laboratories is coupled with regulatory and administrative requirements that must be met, while collaboration between research institutions, industry, and the private sector drives further advancements in the field of breast cancer biomarker discovery and application. e aim of this special issue is to provide new findings regarding molecular pathways and biomarkers that could improve the diagnosis and the prognostic classification of breast cancers, their application in the clinical setting, and their potential utility in personalized patient therapy. e total of submissions is 50. After single-blind peer review by at least two reviewers, 14 papers were finally accepted to be published. e accepted rate is 28%.
- Open Access
- 12 April 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (8) , 1827
Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer
Breast cancer is the most common malignancy in women worldwide and can be categorized into several subtypes according to histopathological parameters or genomic signatures. Such heterogeneity of breast cancer can arise from the reactivation of mammary stem cells in situ during tumorigenesis. Moreover, different breast cancer subtypes exhibit varieties of cancer incidence, therapeutic response, and patient prognosis, suggesting that a specific therapeutic protocol is required for each breast cancer subtype. Recent studies using molecular and cellular assays identified a link between specific genetic/epigenetic alterations and distinct cells of origin of breast cancer subtypes. These alterations include oncogenes, tumor suppressor genes, and cell-lineage determinants, which can induce cell reprogramming (dedifferentiation and transdifferentiation) among two lineage-committed mammary epithelial cells, namely basal and luminal cells. The interconversion of cell states through cell reprogramming into the intermediates of mammary stem cells can give rise to heterogeneous breast cancers that complicate effective therapies of breast cancer. A better understanding of mechanisms underlying cell reprogramming in breast cancer can help in not only elucidating tumorigenesis but also developing therapeutics for breast cancer. This review introduces recent findings on cancer gene-mediated cell reprogramming in breast cancer and discusses the therapeutic potential of targeting cell reprogramming.
- 12 April 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (8) , 1827
Open AccessCell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer
Breast cancer is the most common malignancy in women worldwide and can be categorized into several subtypes according to histopathological parameters or genomic signatures. Such heterogeneity of breast cancer can arise from the reactivation of mammary stem cells in situ during tumorigenesis. Moreover, different breast cancer subtypes exhibit varieties of cancer incidence, therapeutic response, and patient prognosis, suggesting that a specific therapeutic protocol is required for each breast cancer subtype. Recent studies using molecular and cellular assays identified a link between specific genetic/epigenetic alterations and distinct cells of origin of breast cancer subtypes. These alterations include oncogenes, tumor suppressor genes, and cell-lineage determinants, which can induce cell reprogramming (dedifferentiation and transdifferentiation) among two lineage-committed mammary epithelial cells, namely basal and luminal cells. The interconversion of cell states through cell reprogramming into the intermediates of mammary stem cells can give rise to heterogeneous breast cancers that complicate effective therapies of breast cancer. A better understanding of mechanisms underlying cell reprogramming in breast cancer can help in not only elucidating tumorigenesis but also developing therapeutics for breast cancer. This review introduces recent findings on cancer gene-mediated cell reprogramming in breast cancer and discusses the therapeutic potential of targeting cell reprogramming.
- 1 September 2018
- Published by Elsevier in Clinics in Dermatology
- Vol. 36 (5) , 673-679
Synergistic effect of platelet-rich plasma injections and scalp lifting in androgenetic alopecia
- 1 September 2018
- Published by Elsevier in Clinics in Dermatology
- Vol. 36 (5) , 673-679
Synergistic effect of platelet-rich plasma injections and scalp lifting in androgenetic alopecia
- 15 March 2018
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 29 (2) , 241-242
Pyogenic hepatic abscess induced secondary to toothpick penetration of stomach
Cite this article as: Chou DA, Hung MC, Lai JC, Huang WSW. Pyogenic hepatic abscess induced secondary to toothpick penetration of stomach. Turk J Gastroenterol 2018; 29: 241-2.
- 15 March 2018
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 29 (2) , 241-242
Pyogenic hepatic abscess induced secondary to toothpick penetration of stomach
Cite this article as: Chou DA, Hung MC, Lai JC, Huang WSW. Pyogenic hepatic abscess induced secondary to toothpick penetration of stomach. Turk J Gastroenterol 2018; 29: 241-2.
- Open Access
- 5 September 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (68) , 42856-42865
Evaluation of aptamer specificity with or without primers using clinical samples for C-reactive protein by magnetic-assisted rapid aptamer selection
Aptamers with primer binding sites are necessary for the SELEX (Systematic Evolution of Ligands by EXponential enrichment) process.
- 5 September 2017
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 7 (68) , 42856-42865
Open AccessEvaluation of aptamer specificity with or without primers using clinical samples for C-reactive protein by magnetic-assisted rapid aptamer selection
Aptamers with primer binding sites are necessary for the SELEX (Systematic Evolution of Ligands by EXponential enrichment) process.